Our Pipeline

comes from our unique approach

All of our programs are first-in-class and internally generated, each representing an opportunity that can treat numerous diseases.

POC: Proof-of-concept
IND: Investigational new drug
MOA: Mechanism of action

IMMUNOLOGY

ELA026

Myeloid and T cell depletor

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Chart indicating in Early Clinical Development

Additional Indications

Chart indicating in IND Enabling Development

UNDISCLOSED MOA

Autoimmune Diseases

Chart indicating in Discovery Development

IMMUNO-ONCOLOGY

UNDISCLOSED MOA

Various Cancers

Chart indicating in Discovery Development

POC: Proof-of-concept
IND: Investigational new drug
MOA: Mechanism of action